التفاصيل البيبلوغرافية
| العنوان: |
Circulating Immune Cell and Outcome Analysis from the Phase 2 Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent GlioblastomaPD-L1 blockade with durvalumab for glioblastoma |
| المؤلفون: |
Nayak, Lakshmi, Standifer, Nathan, Dietrich, Jorg, Clarke, Jennifer L, Dunn, Gavin P, Lim, Michael, Cloughesy, Timothy, Gan, Hui K, Flagg, Elizabeth, George, Elizabeth, Gaffey, Sarah, Hayden, Julia, Holcroft, Christina, Wen, Patrick Y, Macri, Mary, Park, Andrew J, Ricciardi, Toni, Ryan, Aileen, Schwarzenberger, Paul, Venhaus, Ralph, de los Reyes, Melissa, Durham, Nicholas M, Creasy, Todd, Huang, Raymond Y, Kaley, Thomas, Reardon, David A |
| المصدر: |
Clinical Cancer Research, vol 28, iss 12 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2022 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Brain Disorders, Brain Cancer, Clinical Research, Rare Diseases, Cancer, Antibodies, Monoclonal, B7-H1 Antigen, Bevacizumab, Biomarkers, Tumor, Dexamethasone, Glioblastoma, Humans, Ki-67 Antigen, Neoplasm Recurrence, Local, Oncology & Carcinogenesis, Clinical sciences |
| الوقت: |
2567 - 2578 |
| الوصف: |
PurposePD-L1 is upregulated in glioblastoma and supports immunosuppression. We evaluated PD-L1 blockade with durvalumab among glioblastoma cohorts and investigated potential biomarkers.Patients and methodsMGMT unmethylated newly diagnosed patients received radiotherapy plus durvalumab (cohort A; n = 40). Bevacizumab-naïve, recurrent patients received durvalumab alone (cohort B; n = 31) or in combination with standard bevacizumab (cohort B2; n = 33) or low-dose bevacizumab (cohort B3; n = 33). Bevacizumab-refractory patients received durvalumab plus bevacizumab (cohort C; n = 22). Primary endpoints were: OS-12 (A), PFS-6 (B, B2, B3), and OS-6 (C). Exploratory biomarkers included: a systematic, quantitative, and phenotypic evaluation of circulating immune cells; tumor mutational burden (TMB); and tumor immune activation signature (IAS).ResultsNo cohort achieved the primary efficacy endpoint. Outcome was comparable among recurrent, bevacizumab-naïve cohorts. No unexpected toxicities were observed. A widespread reduction of effector immune cell subsets was noted among recurrent patients compared with newly diagnosed patients that was partially due to dexamethasone use. A trend of increased CD8+Ki67+ T cells at day 15 was noted among patients who achieved the primary endpoint and were not on dexamethasone. Neither TMB nor IAS predicted outcome.ConclusionsPatients with recurrent glioblastoma have markedly lower baseline levels of multiple circulating immune cell subsets compared with newly diagnosed patients. An early increase in systemic Ki67+CD8+ cells may warrant further evaluation as a potential biomarker of therapeutic benefit among patients with glioblastoma undergoing checkpoint therapy. Dexamethasone decreased immune cell subsets. PD-L1 blockade and combination with standard or reduced dose bevacizumab was ineffective. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
unknown |
| العلاقة: |
qt0xc6g5vh; https://escholarship.org/uc/item/0xc6g5vhTest |
| الإتاحة: |
https://escholarship.org/uc/item/0xc6g5vhTest |
| حقوق: |
public |
| رقم الانضمام: |
edsbas.66E044DB |
| قاعدة البيانات: |
BASE |
